RxDoctor Payments Data

Raul Oviedo, MD

Clinical Cardiac Electrophysiology · Chula Vista, CANPI 1972533941

Payments from drug & device makers

$17,394in general payments, 2019–2025

Across 517 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$5K
  • Medtronic$3K
  • Abbott$2K
  • Biosense Webster, Inc.$1K
  • Biotronik Inc.$1K
  • Edwards Lifesciences$657
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$4,87528%
  • Travel & lodging$5883%
  • Food & beverage$11,85768%
  • Education$740%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,394 in reported general payments places this provider in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$412,421
Medicare patients
561
Services billed
4,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban328$378,884
EntrestoSacubitril/Valsartan155$178,150
XareltoRivaroxaban59$78,100
BrilintaTicagrelor19$19,391
MultaqDronedarone Hcl17$15,578
JardianceEmpagliflozin13$14,027
Carvedilol588$11,059
Repatha SureclickEvolocumab16$9,091
Nifedipine ErNifedipine233$6,984
Losartan Potassium267$4,705
FarxigaDapagliflozin Propanediol11$4,589
Atorvastatin Calcium285$4,577
Amlodipine Besylate336$4,248
Lisinopril231$2,757
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine17$2,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$378,884328 claims
NovartisEntresto$550$178,150155 claims
Johnson & JohnsonXarelto$329$78,10059 claims
AstraZenecaBrilinta, Farxiga$96$23,98030 claims
Sanofi-aventis U.S. LLCMultaq$199$15,57817 claims
Boehringer IngelheimJardiance$117$14,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →